KRSNAA DIAGNOSTICS LTD Q4 RESULTS
Getting ready to end the 3-year exile: 5 stocks from diagnostics sector with upside potential of up to 53%
There are some businesses, where only a black swan event leads to sharp growth in profit. Otherwise the underlying nature is such that they don't have any sudden spike in their profits. But there is constant growth. The constant growth could be because of many reasons. It may be because of the fact that penetration of that good or service is very low and over a period of time as it improves, both top and bottom line keep moving upward. It could be because of the movement of business from the unorganized sector to the organized sector. Or due the fact that the “need” of that good or service is such that spending on it cannot be postponed. In the case of diagnostic business, it is all the three, or rather four. The fact is that in 2020, a black swan took place which led to the sudden spike in FY 2021 numbers, but then back to normal growth curve. Now for three years, there has been a painful process of partial normalization of valuation and end of price wars. Has the time come for extreme long term investors to bring them back on watchlist ?
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
Apollo Hospitals Q4 Results: Net profit rises 76% YoY to Rs 254 crore
Revenue grew 15% YoY to Rs.4,944 crore in Q4FY24. The earnings before interest, tax, depreciation and ammortisation (EBITDA), EBITDA rose 31% YoY to Rs.640 crore in Q4FY24. The EBITDA margins expanded 161 basis points YoY to 12.95%.
Apollo Hospitals Q4 Results: Net profit soars 77% YoY to Rs 258 crore; revenue jumps 15%
Apollo Hospitals Q4 Results: Revenue from operations for the January-March 2024 period increased 15% YoY to Rs 4,944 crore. The company's board has recommended a final dividend of Rs 10 per share for FY24. EBITDA for the fourth quarter stood at Rs 640 crore in the reporting March quarter, compared with Rs 488 crore in the same quarter a year earlier.
Apollo Hospitals Q4 results today: What to expect
Apollo Hospitals is expected to post healthy growth in core earnings for the quarter ended March 2024 due to improved ARPOB and Healthco operations. Analysts predict a 68% year-on-year growth in net profit for the fourth quarter.
Q4 results today: Apollo Hospitals among 895 companies to announce earnings on Thursday
Fourth quarter earnings season is wrapping up with 895 companies reporting results on Thursday. Investors keenly await Apollo Hospitals' results, expecting robust growth driven by improved ARPOB and HealthCo operations. Analysts predict up to a 68% YoY increase in net profit, with sales expected to rise by 13%.
- Go To Page 1
Fortis Healthcare Q4 Results: Net profit jumps 47% YoY to Rs 203 crore
Fortis Healthcare Ltd on Thursday reported a 46.88 per cent increase in consolidated net profit at Rs 203.14 crore in the fourth quarter ended March 2024 on the back of higher revenue from its core business.
Metropolis Healthcare Q4 Results: Net profit rises 8% to Rs 36 crore
The diagnostic chain reported Rs 33.5 crore net profit in the corresponding quarter of the previous year. Revenue from operations grew by 11% YoY to Rs 313 crore.
Dr Lal PathLabs shares zoom 8% after Q4 results. Should you buy or sell?
Dr Lal PathLabs saw an 8% surge in shares to Rs 2,539.65 on the BSE following a 51% YoY increase in net profit to Rs 86 crore for Q4FY24. Analysts have varying opinions, with Kotak and JM Financial maintaining positive outlooks, while Goldman Sachs remains cautious.
Do Dr Lal Pathlabs' results indicate a turnaround for the sector? 4 stocks from diagnostic space, 3 with upside potential of up to 31%
Some sectors have a company which can be called as the bell weather of that sector and that is why its results of that company probably are indicative of what is happening in the sector. In case of the diagnostic, it is probably the Dr Lals path labs which would fit the criteria, it has national presence, large network, present in both physical and digital segment. So when the quarterly numbers come and they show improvement on many fronts then probably it is time to have a look at them more seriously and see if there is a possible turnaround building in the sector. This became even more important because these stocks had gained extremely high valuation and also popularity in terms of both retail and institutional participation. But then for close to two years, they have been a strong under performer in a strong bull market. Does this result mean that finally in terms of price war for customer acquisition over and now the valuation readjustment will start in the upward direction.
Dr Lal PathLabs Q4 Results: Net profit rises 51% YoY to Rs 86 crore on improved volumes of diagnostic tests
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
Dr. LalPath Labs Q4 Reslts: Firm posts higher profit on healthy testing demand
Its shares climbed as much as 7.8% after the results before trimming some gains to trade up about 6%. Rival Metropolis Healthcare was up about 2% and Thyrocare Technologies gained about 1%.
Volatility is an integral part of market: 4 midcap stocks from different sectors with potential upside of up to 39%
As the market gets volatile, questions are bound to be raised about whether the mid-cap segment would see a sharp correction or not. Fears about the kind of correction which was seen in March are bound to resurface. More than anything, the best way to navigate such market conditions would be to do two things, first stay with mid-cap stock with some track record in terms of fundamentals and give return to shareholders. Second, once you pick the stock, stay with it long term and dont sell in hurry due to any narrative which some global and domestic development might bring on the table. The reason, volatility is part of any market, but that should not determine your long term investment decisions. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
Tackling volatility, qualitative & quantitative way: 4 small cap stocks with long term perspective
The way the market slipped on Friday, probably is another reminder that even the best of the bull market corrections are going to come. The problem with the corrective move is that if it sustains for longer, it is the small caps stocks which come under more pressure and shed an inordinate amount of weight. There is a technical reason for this, the liquidity in small caps stocks is lower as compared to large and midcaps. So, whenever there is a selling in this segment, the impact cost is always higher. But the other fact is that if one is able to hold on small at the time when correction is taking place, probability of more than normal return is also higher. But the question is how does one develop the ability to hold onto stocks when the narrative which is being governed by price action becomes so negative. The solution lies in combining a couple of things, which include qualitative and quantitative measure and last but not least ability to ignore noise.
Q4 results this week: SBI, Tata Motors, L&T, Asian Paints, TVS Motor and PB Fintech
Various widely tracked companies like Tata Motors, SBI, Asian Paints, BPCL, Larsen & Toubro, Tata Power, Canara Bank, TVS Motor, Hero MotoCorp, Godrej Consumer Products, JSW Energy, Dr. Reddy's Laboratories, PB Fintech, and Bank of Baroda will be releasing their March quarter report cards this week. Here’s a list:
Painful readjustment of valuations over? 4 stocks from diagnostics sector with upside potential of up to 31%
In the last four years, many sectors have made a comeback. However, there are few, who have probably a full life cycle in this short period of time. From all the love on the street which made them touch dizzy heights of valuations. Then a realization that the street is paying too much for them. It is about the diagnostic sector. From being part of a star portfolio manager tops picks, to him admitting that he made a mistake. Diagnostic stocks have seen a cycle. There is another side to the story. Every sector which goes through such cycles in the short term, tends to see a recovery. The only difference is the recovery time, both of the business and getting recognised once again by the street. So, these stocks will make a comeback, whether it happens in one quarter or after years is the question. But one thing is for sure, that if you are a long term investor, don't be in a hurry to get out of the sector.
GE HealthCare Q1 Results: Co misses quarterly revenue estimates on weakness in China market
GE HealthCare Technologies missed first-quarter revenue estimates on Tuesday, hurt by lower sales in China market and weaker-than-expected demand for its scanning devices, sending its shares tumbling as much as 12% before the bell.
Q4 results this week: RIL, ICICI Bank, HCL Tech, among 166 companies that'll announce earnings
With Wipro and Infosys’ results out this week, the fourth quarter earnings season will now pick up pace as the upcoming week will witness the results for Axis Bank, ICICI Prudential Life Insurance, Mahindra & Mahindra Financial Services, Tata Elxsi, along with 167 other companies.
Gear up for a muted Q4; IT, pharma, metal may disappoint: S Krishnakumar
S Krishnakumar shares insights on market performance, cautioning on high valuations and potential earnings surprises in auto ancillaries. He highlights megatrends in renewables, e-commerce, and manufacturing, stressing the need for strategic investment timing. Krishnakumar further says that "opportunities are very rare to come by where there is a lot more comfort in valuation. This is a market which is well priced in ."
Process of overvaluations getting readjusted over? 4 stocks from diagnostics sector with upside potential of 18-23%
There are some businesses whose underlying nature is such that they don't have any sudden spike in their profits. However at the same time, there is constant growth. The growth could be because of many reasons, it may be because of the fact that penetration of that good or service is very low and over a period of time as it improves, both top and bottom line keep moving upward. In some cases, it could be because of the movement of business from the unorganized sector to the organized sector. It could also be because of the fact that the need is such that if required spending on it cannot be postponed. In the case of diagnostic business, it is all the three. But there is another side to it, how the street is treating these businesses when it comes to valuations. In case of diagnostics, from dizzy heights of valuation in 2021 to today where it is being seen as a sector where there is nothing worth looking at this point of time due to multiple issues. Yes, there are real issues with the business, but not a bad time to get them on watchlist at least.
Apollo Hospitals Q3 Results: Cons PAT soars 59% YoY to Rs 245 crore; dividend declared at Rs 6/share
Apollo Hospitals' revenue from operations grew 14% YoY to Rs 4,851 crore, and topped the estimated Rs 4,771 crore. The healthcare services business saw a healthy 13% YoY growth in revenue during the quarter to Rs 2,483 crore, followed by the pharmacy distribution business housed under Apollo Pharmacy, which registered 17% growth in revenue to Rs 2,049 crore.
Fortis Healthcare Q3 Results: Net profit drops 11% YoY to Rs 134 crore
The operating earnings before interest, tax, depreciation and amortisation (EBITDA) rose 6.8% YoY to Rs 284 crore. The EBITDA margins declined 80 basis points to 16.9%.
Dr. Lal PathLabs Q3 Results: Firm posts 54% jump in profit on flu, COVID tests
The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu.
Price wars are still on but... 4 stocks from diagnostics sector have upside potential of up to 26%
In the last five years, the diagnostic segment of the healthcare sector has seen many ups and downs. During Covid, diagnostic players were overloaded with work and then came the price wars which some new tech companies brought on the table. The price war was essentially started to grab both, market and mind share. While the price war is still on in some segments, there is a possibility that its intensity may come down. The reason, new companies have burnt enough cash and large physical-only players have also made some inroads into digital channels for customer acquisition and also part delivery of the service. Will this bring back focus of the street?
Fortis Healthcare Q1 Results: PAT falls 9% YoY to Rs 122.5 cr
The company, which posted a consolidated profit after tax of Rs 134.3 crore in the first quarter of the last fiscal, said its diagnostics business has been renamed as Agilus Diagnostics Ltd, and the boards of the two firms have granted approval for the latter to initiate an initial public offer (IPO) process
Fortis board gives nod for diagnostic arm IPO, net profit drops 9% in Q1FY24
Agilus was earlier called SRL Diagnostics, which was rebranded in May this year. Fortis Healthcare on Friday reported a 9% year-on-year (YoY) drop in net profit to Rs 122.5 crore in Q1FY24
For risk takers: 5 smallcap stocks that have beaten volatile markets can rise up to 58%
As Nifty comes closer to form a new high, more small cap stocks are joining the party. Right from a logistic company of a large industrial house to a diagnostic major to quick service restaurant players are coming on the list. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
For risk takers: 5 smallcap stocks that have beaten volatile markets can rise up to 52%
As Nifty comes closer to form a new high, more small cap stocks are joining the party. Right from a power and a diagnostic major to an engineering company are coming on the list. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
Dr. Lal PathLabs Q4 Results: Co reports sixth consecutive fall in net profit at Rs 567 million
The medical diagnostics firm, India's largest by revenue, posted a consolidated net profit of 567 million rupees ($6.93 million) in the three months to March 31, down from 613 million rupees a year earlier.
Load More
